Loading...
•
Mar 31, 2022
NeoGenomics Q1 2022 Earnings Report
NeoGenomics reported a slight revenue increase, but experienced a net loss due to increased operating expenses and amortization of acquired technology.
Key Takeaways
NeoGenomics reported a 1% increase in consolidated revenue to $117 million for Q1 2022. Clinical Services revenue increased by 2%, while Pharma Services revenue decreased by 4%. The company experienced a net loss of $49 million, compared to a net loss of $22 million in the same period last year, due to increased operating expenses and amortization of acquired technology.
Consolidated revenue increased 1% to $117 million.
Clinical Services revenue increased 2% to $99 million.
Pharma Services revenue decreased 4% to $18 million.
Net loss for the quarter was $49 million.
Forward Guidance
The company is focused on improving operating performance and returning to profitable growth.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...